150 related articles for article (PubMed ID: 38764773)
1. Angiotensin-converting enzyme 2 and AMPK/mTOR pathway in the treatment of liver fibrosis: Should we consider further implications?
Barone M
World J Gastroenterol; 2024 May; 30(18):2391-2396. PubMed ID: 38764773
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme 2 improves liver fibrosis in mice by regulating autophagy of hepatic stellate cells.
Wu Y; Yin AH; Sun JT; Xu WH; Zhang CQ
World J Gastroenterol; 2023 Sep; 29(33):4975-4990. PubMed ID: 37732000
[TBL] [Abstract][Full Text] [Related]
3. Sestrin 2 Attenuates Rat Hepatic Stellate Cell (HSC) Activation and Liver Fibrosis via an mTOR/AMPK-Dependent Mechanism.
Hu YB; Ye XT; Zhou QQ; Fu RQ
Cell Physiol Biochem; 2018; 51(5):2111-2122. PubMed ID: 30522100
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
Yoshiji H; Kuriyama S; Fukui H
Tumour Biol; 2002; 23(6):348-56. PubMed ID: 12677092
[TBL] [Abstract][Full Text] [Related]
5. The role of renin angiotensin system in the pathophysiology of rheumatoid arthritis.
Moreira FRC; de Oliveira TA; Ramos NE; Abreu MAD; Simões E Silva AC
Mol Biol Rep; 2021 Sep; 48(9):6619-6629. PubMed ID: 34417705
[TBL] [Abstract][Full Text] [Related]
6. Hepatic fibrosis and the renin-angiotensin system.
Abbas G; Silveira MG; Lindor KD
Am J Ther; 2011 Nov; 18(6):e202-8. PubMed ID: 20535005
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice.
Osterreicher CH; Taura K; De Minicis S; Seki E; Penz-Osterreicher M; Kodama Y; Kluwe J; Schuster M; Oudit GY; Penninger JM; Brenner DA
Hepatology; 2009 Sep; 50(3):929-38. PubMed ID: 19650157
[TBL] [Abstract][Full Text] [Related]
8. Alamandine attenuates hepatic fibrosis by regulating autophagy induced by NOX4-dependent ROS.
Huang Y; Li Y; Lou A; Wang GZ; Hu Y; Zhang Y; Huang W; Wang J; Li Y; Zhu X; Chen T; Lin J; Meng Y; Li X
Clin Sci (Lond); 2020 Apr; 134(7):853-869. PubMed ID: 32227122
[TBL] [Abstract][Full Text] [Related]
9. The role of the renin-angiotensin system in liver fibrosis.
Munshi MK; Uddin MN; Glaser SS
Exp Biol Med (Maywood); 2011 May; 236(5):557-66. PubMed ID: 21508249
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme 2 alleviates liver fibrosis through the renin-angiotensin system.
Zhao BW; Chen YJ; Zhang RP; Chen YM; Huang BW
World J Gastroenterol; 2024 Feb; 30(6):607-609. PubMed ID: 38463024
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors.
Huang ML; Li X; Meng Y; Xiao B; Ma Q; Ying SS; Wu PS; Zhang ZS
Clin Exp Pharmacol Physiol; 2010 Jan; 37(1):e1-6. PubMed ID: 19793108
[TBL] [Abstract][Full Text] [Related]
12. Role of renin-angiotensin system in liver diseases: an outline on the potential therapeutic points of intervention.
Ahmadian E; Pennefather PS; Eftekhari A; Heidari R; Eghbal MA
Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1279-1288. PubMed ID: 27352778
[TBL] [Abstract][Full Text] [Related]
13. Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.
Lubel JS; Herath CB; Burrell LM; Angus PW
J Gastroenterol Hepatol; 2008 Sep; 23(9):1327-38. PubMed ID: 18557800
[TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin system blockade on angiotensin-converting enzyme 2 and TMPRSS2 in human type II pneumocytes.
Silva MG; Falcoff NL; Corradi GR; Alfie J; Seguel RF; Tabaj GC; Iglesias LI; Nuñez M; Guman GR; Gironacci MM
Life Sci; 2022 Mar; 293():120324. PubMed ID: 35032553
[TBL] [Abstract][Full Text] [Related]
15. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway.
Grouix B; Sarra-Bournet F; Leduc M; Simard JC; Hince K; Geerts L; Blais A; Gervais L; Laverdure A; Felton A; Richard J; Ouboudinar J; Gagnon W; Leblond FA; Laurin P; Gagnon L
J Pharmacol Exp Ther; 2018 Oct; 367(1):71-81. PubMed ID: 30093459
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme 2 ameliorates renal fibrosis by blocking the activation of mTOR/ERK signaling in apolipoprotein E-deficient mice.
Chen LJ; Xu YL; Song B; Yu HM; Oudit GY; Xu R; Zhang ZZ; Jin HY; Chang Q; Zhu DL; Zhong JC
Peptides; 2016 May; 79():49-57. PubMed ID: 27018342
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases.
Yoshiji H; Noguchi R; Ikenaka Y; Kitade M; Kaji K; Tsujimoto T; Uemura M; Fukui H
Curr Med Chem; 2007; 14(26):2749-54. PubMed ID: 18045121
[TBL] [Abstract][Full Text] [Related]
18. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases.
Moreira de Macêdo S; Guimarães TA; Feltenberger JD; Sousa Santos SH
Peptides; 2014 Dec; 62():189-96. PubMed ID: 25453980
[TBL] [Abstract][Full Text] [Related]
19. AICAR and compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro.
Böttcher K; Longato L; Marrone G; Mazza G; Ghemtio L; Hall A; Luong TV; Caruso S; Viollet B; Zucman-Rossi J; Pinzani M; Rombouts K
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G543-G556. PubMed ID: 33406006
[TBL] [Abstract][Full Text] [Related]
20. The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma.
Ye G; Qin Y; Lu X; Xu X; Xu S; Wu C; Wang X; Wang S; Pan D
Biochem Biophys Res Commun; 2015 Mar; 459(1):18-23. PubMed ID: 25701390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]